Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Study: Routine testing with FISH and IHC may enhance detection of ALK-positive NSCLC

The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC).

25 Feb 2014

Predictors of bone metastasis, skeletal events in lung cancer identified

Researchers have identified a range of factors that are associated with the likelihood that a patient with advanced lung cancer will develop bone metastases or skeletal-related events.

20 Feb 2014

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

20 Feb 2014

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease progression after first-line chemotherapy, phase III study results show.

19 Feb 2014

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend.

17 Feb 2014

New study documents frequency of EGFR mutations in lung adenocarcinoma in Asian population

Adenocarcinoma histology, female sex, never-smoking status, and Asian ethnicity have been considered the most important factors associated with EGFR mutations in non-small cell lung cancer and response to EGFR inhibitors. A recent study has found that, within the Asian population, the frequency of EGFR mutations associated with other demographic and clinical characteristics is higher than previously reported, even in patients with a history of smoking, suggesting that mutation testing should be done on a broader basis among Asian patients with advanced adenocarcinoma of the lung.

16 Feb 2014

Study shows how Bcl-2 cancer-related protein signals cancer cells to live longer

A team of researchers from Case Western Reserve School of Medicine has discovered how the cancer-related protein Bcl-2 signals cancer cells to live longer.

14 Feb 2014

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.

5 Feb 2014

Primary tumor, node location important in stage III NSCLC prognosis

Researchers from Japan say that classifying clinical mediastinal lymph node status based on the location of the primary tumor and the node involved could improve prognosis in stage III non-small-cell lung cancer compared with pathologic node status.

3 Feb 2014

TSRI scientists awarded grant to develop new therapeutic approaches for lung cancer

Scientists from the Florida campus of The Scripps Research Institute have been awarded approximately $1.8 million from the National Cancer Institute of the National Institutes of Health to identify the signaling pathways that underlie lung cancer and to use this information to develop new therapeutic approaches.

30 Jan 2014

EORTC study evaluates health-related quality of life assessment in small-cell lung cancer

An EORTC study published in Lancet Oncology found that health-related quality of life assessment in small-cell lung cancer randomized clinical trials provides relevant added information in studies where the treatment arms do not differ in terms of efficacy.

29 Jan 2014

Everolimus fails to boost advanced NSCLC response

Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.

28 Jan 2014

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer.

28 Jan 2014

BRAF mutations rare in Japanese NSCLC patients

Research in a Japanese cohort of patients with non-small-cell lung cancer indicates that the frequency of BRAF mutations is low and their presence has limited prognostic significance.

27 Jan 2014

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma.

25 Jan 2014

Immunotherapy maintenance shows promise in NSCLC

Results from a phase III trial have shown that tecemotide is no more effective than placebo as maintenance therapy in patients with non-small-cell lung cancer.

24 Jan 2014

Novel HER2 mutation identified in familial lung adenocarcinomas

Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas.

24 Jan 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

Etoposide plus cisplatin remains best for limited-stage SCLC

Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say.

23 Jan 2014

UT Southwestern' faculty receives Stanley J. Korsmeyer Award for contributions to understanding of autophagy

Dr. Beth Levine, a Howard Hughes Medical Institute Investigator and Director of the Center for Autophagy Research at UT Southwestern Medical Center, has received the 2014 Stanley J. Korsmeyer Award from the American Society for Clinical Investigation.

22 Jan 2014

Small Cell Lung Cancer News and Research

Study: Routine testing with FISH and IHC may enhance detection of ALK-positive NSCLC

Predictors of bone metastasis, skeletal events in lung cancer identified

Lung cancer patients with Del19 mutation benefit most from afatinib

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Afatinib ‘first line’ for advanced mutation-positive lung cancer

New study documents frequency of EGFR mutations in lung adenocarcinoma in Asian population

Study shows how Bcl-2 cancer-related protein signals cancer cells to live longer

Incyte enters into clinical trial collaboration agreement with Merck to evaluate safety of IDO1 inhibitor

Primary tumor, node location important in stage III NSCLC prognosis

TSRI scientists awarded grant to develop new therapeutic approaches for lung cancer

EORTC study evaluates health-related quality of life assessment in small-cell lung cancer

Everolimus fails to boost advanced NSCLC response

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

BRAF mutations rare in Japanese NSCLC patients

First patient enrolled pilot clinical trial of NovoTTF Therapy plus gemcitabine for pancreatic adenocarcinoma

Immunotherapy maintenance shows promise in NSCLC

Novel HER2 mutation identified in familial lung adenocarcinomas

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Etoposide plus cisplatin remains best for limited-stage SCLC

UT Southwestern' faculty receives Stanley J. Korsmeyer Award for contributions to understanding of autophagy

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News